Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:MXCT NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$65.13+18.2%$44.08$30.04▼$66.10$5.62B1.821.99 million shs10.14 million shsMXCTMaxCyte$2.02-6.0%$2.22$2.00▼$5.20$214.97M1.23612,947 shs387,474 shsVRTXVertex Pharmaceuticals$459.81-0.7%$448.80$377.85▼$519.88$118.08B0.411.42 million shs970,576 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-0.09%-6.63%+27.55%+45.86%-8.91%MXCTMaxCyte+1.42%-5.70%0.00%-17.62%-57.17%VRTXVertex Pharmaceuticals-1.34%-3.39%+4.81%-5.28%-5.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics2.6882 of 5 stars3.31.00.00.03.33.30.6MXCTMaxCyte2.8028 of 5 stars3.54.00.00.01.61.70.6VRTXVertex Pharmaceuticals4.7272 of 5 stars3.35.00.03.34.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7510.83% UpsideMXCTMaxCyte 3.00Buy$7.50266.75% UpsideVRTXVertex Pharmaceuticals 2.54Moderate Buy$511.7111.33% UpsideCurrent Analyst Ratings BreakdownLatest MXCT, VRTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025VRTXVertex PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$515.00 ➝ $517.007/8/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/23/2025VRTXVertex PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$550.006/20/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.006/17/2025VRTXVertex PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.005/23/2025VRTXVertex PharmaceuticalsErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M149.85N/AN/A$22.64 per share2.86MXCTMaxCyte$38.63M5.63N/AN/A$1.95 per share1.05VRTXVertex Pharmaceuticals$11.02B10.71N/AN/A$63.72 per share7.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)MXCTMaxCyte-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/6/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$3.92N/A26.25N/A-8.91%-3.36%-2.42%8/4/2025 (Confirmed)Latest MXCT, VRTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025VRTXVertex Pharmaceuticals$4.24N/AN/AN/A$2.90 billionN/A8/6/2025Q2 2025MXCTMaxCyte-$0.10N/AN/AN/A$9.57 millionN/A8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.54N/AN/AN/A$6.44 millionN/A5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A15.6415.64MXCTMaxCyteN/A12.2311.58VRTXVertex Pharmaceuticals0.012.652.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%MXCTMaxCyte68.81%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%MXCTMaxCyte3.30%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46086.36 million82.65 millionOptionableMXCTMaxCyte80106.42 million102.90 millionOptionableVRTXVertex Pharmaceuticals6,100256.80 million256.28 millionOptionableMXCT, VRTX, and CRSP HeadlinesRecent News About These CompaniesMystic Asset Management Inc. Invests $970,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)5 hours ago | marketbeat.comNwam LLC Sells 1,436 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 11:12 AM | marketbeat.comDiversify Advisory Services LLC Purchases 827 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 11:09 AM | marketbeat.comC WorldWide Group Holding A S Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 10:27 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Raised by Jennison Associates LLCJuly 18 at 9:29 AM | marketbeat.comCwm LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 18 at 4:42 AM | marketbeat.com2,000 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Retirement Planning Co of New England Inc.July 17 at 9:41 AM | marketbeat.comVictory Capital Management Inc. Sells 11,261 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 17 at 6:51 AM | marketbeat.comWhat is William Blair's Forecast for VRTX FY2025 Earnings?July 17 at 3:31 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItJuly 16 at 10:01 AM | zacks.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 16 at 9:51 AM | zacks.comTriasima Portfolio Management inc. Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16 at 8:59 AM | marketbeat.comWelch & Forbes LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16 at 8:44 AM | marketbeat.comGrandfield & Dodd LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16 at 8:34 AM | marketbeat.comSegall Bryant & Hamill LLC Has $25.61 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16 at 7:54 AM | marketbeat.comBridgewater Advisors Inc. Purchases Shares of 1,113 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16 at 7:09 AM | marketbeat.comWilliam Blair Has Negative Outlook for VRTX FY2025 EarningsJuly 16 at 6:46 AM | marketbeat.comPAX Financial Group LLC Takes $316,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)July 16 at 6:44 AM | marketbeat.comVertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic ExpansionsJuly 16 at 6:24 AM | tipranks.comVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $517.00July 16 at 3:01 AM | americanbankingnews.comEquities Analysts Offer Predictions for VRTX Q2 EarningsJuly 16 at 2:21 AM | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMXCT, VRTX, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$65.13 +10.04 (+18.22%) Closing price 04:00 PM EasternExtended Trading$64.90 -0.23 (-0.36%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.MaxCyte NASDAQ:MXCT$2.02 -0.13 (-6.05%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.00 (+0.25%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Vertex Pharmaceuticals NASDAQ:VRTX$459.81 -3.46 (-0.75%) Closing price 04:00 PM EasternExtended Trading$459.78 -0.02 (-0.01%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
